Arrowstreet Capital’s Celldex Therapeutics CLDX Stock Holding History

Arrowstreet Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-44,356	Closed	-$2.4M	–	1471
2021 Q3	$2.4M	Buy	+44,356	New	+$2.08M	﹤0.01%	1092
2016 Q4	–	Sell	-18,329	Closed	-$1.11M	–	1769
2016 Q3	$1.11M	Buy	+18,329	New	+$1.14M	﹤0.01%	1053
2014 Q2	–	Sell	-7,958	Closed	-$2.11M	–	1006
2014 Q1	$2.11M	Sell	7,958 -23,827	-75%	-$9.12M	0.01%	647
2013 Q4	$11.5M	Buy	+31,785	New	+$12.2M	0.06%	267

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Arrowstreet Capital's CLDX Position: Q4 2021 in Review

Arrowstreet Capital sold out of Celldex Therapeutics (CLDX) in Q4 2021, closing a stake of 44,356 shares — an estimated $2.4M sold.

Arrowstreet Capital first reported a position in CLDX in Q4 2013 and held it in 4 quarters. The position peaked at $11.5M in Q4 2013. 180 funds tracked by Wall St. Rank hold CLDX as of Q4 2021.

Arrowstreet Capital reported no remaining Celldex Therapeutics position as of Q4 2021 after selling out during the quarter.
Arrowstreet Capital sold 44,356 Celldex Therapeutics shares in Q4 2021, an estimated $2.4M.
Arrowstreet Capital first reported a position in Celldex Therapeutics in Q4 2013 and held it in 4 quarters.
Arrowstreet Capital's Celldex Therapeutics position peaked at $11.5M in Q4 2013.
180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2021.

Based on Arrowstreet Capital's 13F filing for Q4 2021, filed 14 Feb 2022.